Piramal Pharma Ltd reports Q2FY27 revenue of ₹2,617 crore, up 28% YoY, and raises FY27 growth outlook to 19–20%
- EBITDA rose 72% YoY to ₹385 crore; margin expanded to 14.7% from 11.0%.
- Net profit was ₹5 crore versus a ₹99 crore loss in Q2FY26; Q1FY27 had a ₹69 crore loss.
- H1FY27 included a ₹21 crore exceptional gain from one-time insolvency proceeds; Q2FY27 had no exceptional item.
- Results are unaudited.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a320fcd-724c-4a4e-8f42-f4f9c627ed63.pdf